Plain-English translation of NCT06510868 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research is examining genetic changes in your blood to understand a rare but serious long-term side effect that can develop after peptide radionuclide therapy (PRRT)—a targeted radiation treatment for neuroendocrine tumors. Researchers want to identify genetic markers that might predict which patients are at higher risk for developing blood disorders like myelodysplastic syndrome or acute myeloid leukemia after this treatment, so doctors can better protect patients in the future.
While this medication is effective at treating neuroendocrine tumors, some patients develop blood cell disorders years later—a serious complication that is hard to predict. By studying genetic patterns before, during, and after treatment, researchers hope to identify which patients are at highest risk and develop ways to prevent or catch these complications earlier.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you will either provide blood samples once (if you've already completed PRRT), at multiple timepoints before and after starting PRRT (if you're about to begin), or once if you've already developed a blood disorder after treatment. Each visit involves a blood draw, which takes about 10–15 minutes. Researchers will use these samples to study genetic changes over time, with the goal of identifying patterns that help predict treatment complications in future patients.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Canada